Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.
- German biotech 4SC has launched a Phase Ib/II study of its small molecule drug candidate for melanoma, with results expected later this year.
- European diagnostics firm Curetis has started an antibiotic stewardship program for pharmaceutical companies and contract research organizations through its subsidiary company Ares Genetics, which is based in Austria.
- UK life sciences group Abzena has partnered with New York University’s Langone Health Center to help it develop new drugs. The first application will be for the treatment of severe autoimmune diseases.
- A device developed by Israeli company Rapid Medical to remove clots from small blood vessels in the brain has been granted a CE Mark, with over 1000 patients treated to date.
- Israeli cancer specialist Novocure published positive results from its Innovate Phase II study showing its electric current based therapy can extend progression-free survival in patients with recurrent ovarian cancer.
- Mologic, in the UK, has started a clinical trial of a urine test for cystic fibrosis intended to determine whether the patient requires medical intervention.
- The EMA has fast-tracked the marketing authorization of LentiGlobin, a gene therapy for the rare blood disease transfusion-dependent thalassemia, which is being developed by bluebird bio.
- Carmat has reported the first case of a patient that has received a successful heart transplant after living 8 months with the company’s artificial heart, which helped improve his condition and become eligible for a transplant.
- ADL Bionatur Solutions, a Spanish company with expertise in industrial fermentation, closed a €12M fundraising round following its listing in May on the Mercado Alternativo Bursátil.
- A project to develop fuels from biological sources, called reFuels, has been launched at the Karlsruhe Institute of Technology and joined by multiple industrial partners, including the Petroleum Industry Association, Audi, Porsche, and Rolls-Royce.
- UK-based start-up Entomics Biosystems is using a specific fermentation process to boost the nutritional value of fish and animal food made from insects such as maggots.
Images via Shutterstock
Let's Continue The Conversation
Feel free to send us comments about this article to email@example.com and/or comment on that article on social media.